FOXO4-DRI is sold here for laboratory research, in 2 sizes (2mg to 10mg), starting at $55.00 a vial. Every batch arrives with a certificate naming the test that identified it, the test that measured its purity, and the date each was run. It is not an FDA-approved medicine. Research use only, and never for people or animals.
FOXO4-DRI specifications
| Product name | FOXO4-DRI |
|---|---|
| Also sold as | FOXO4-DRI peptide |
| Formula | C228H388N86O64 |
| Physical form | Freeze-dried powder — a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 2mg · 10mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | At the laboratory — each certificate posts here the day it clears |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California — same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is FOXO4-DRI?
FOXO4-DRI is also listed and searched as FOXO4-DRI peptide. They all mean the same compound. Supplier lists write it as peptide FOXO4-DRI as well; every one of those is this record. A name is not a test, which is why the lot record further down counts for more than the wording on a label.
Chemically: molecular formula C228H388N86O64, average mass 5358 g/mol (PubChem CID 167312269). Those figures are what the identity test on a certificate is read against.
A D-retro-inverso peptide: a cell-penetrating peptide built from D-amino acids in reversed sequence order, designed to resist proteolysis while preserving the side-chain topology of the native FOXO4 sequence.
Perturbs the interaction between FOXO4 and p53. In senescent cells this causes p53 nuclear exclusion and cell-intrinsic apoptosis — a senolytic mechanism that exploits how senescent cells specifically avoid dying.
Senescent cell clearance, doxorubicin-induced chemotoxicity, and fast-ageing and naturally aged mouse models.
No human data, no approved product. The published in vivo work is explicitly qualified as being conducted under conditions where the peptide was well tolerated, which is itself a statement about a therapeutic window.
FOXO4-DRI for sale: 2mg and 10mg vials, price per mg
FOXO4-DRI cost, and FOXO4-DRI price per mg by size
FOXO4-DRI is sold in 2 sizes here, 2mg and 10mg, from $55.00 a vial. FOXO4-DRI cost starts at that figure for the smallest vial, and the FOXO4-DRI price per mg in the second column is the number to compare between sizes. The per-mg column is the honest comparison between sizes; the two tier columns show what ten and twenty vials of one size bill at, because the volume discount is per size and mixed sizes do not combine.
| Size | One vial | Per mg | 10 vials −10% | 20 vials −15% | Availability |
|---|---|---|---|---|---|
| FOXO4-DRI 2mg | $55.00 | $27.50 | $495.00$24.75/mg | $935.00$23.38/mg | Backordered — waitlist |
| FOXO4-DRI 10mg | $175.00 | $17.50 | $1,575.00$15.75/mg | $2,975.00$14.88/mg | Backordered — waitlist |
FOXO4-DRI discounts: bulk pricing, Subscribe & Save, and codes
Three things move this price and nothing else does: how many vials of one size are on the order, whether that order repeats, and one code. The fourth column prices each route against the 2mg vial.
| Buying option | Takes off | When it applies | 2mg at this option |
|---|---|---|---|
| One vial, one time | — | Any order | $55.00 |
| 10–19 vials of one size | 10% | This order | $495.00$49.50 a vial |
| 20 vials of one size | 15% | This order | $935.00$46.75 a vial |
| Subscribe, every 1 month | 6% | Shipment 2 onward | First $55.00, then $51.70 |
| Subscribe, every 2 months | 4% | Shipment 2 onward | First $55.00, then $52.80 |
| Subscribe, every 3 months | 2% | Shipment 2 onward | First $55.00, then $53.90 |
| 10 vials on a monthly subscription | 10%, then 6% more | Shipment 2 onward | First $495.00, then $465.30 |
| Sign-up code | 10% of the order | One use, dead 24 hours after signup | $49.50 for one vial |
| Friday newsletter code | 5% of the order | Live 24 hours, a new one each Friday | $52.25 for one vial |
| On-site offer code | 5% of the order | Live 30 minutes from when it appears | $52.25 for one vial |
| Free standard shipping | The shipping charge | Orders over $200 | 4 vials |
The first three stack; the codes do not. A volume discount comes off the line, a subscription cadence comes off that same line from shipment 2, and one code comes off what is left. One code per order, never two. A subscription runs a minimum of two shipments and can be cancelled once the second has shipped, and the first shipment always bills at today's eligible price with no cadence discount on it. The lowest this record ever bills is $21.97 per mg: twenty 2mg vials on a monthly subscription, from shipment 2 onward.
Every figure above is what you pay; nothing is added at checkout — dispatch and delivery work the same on every order.
Where to buy FOXO4-DRI: five checks before you order from anyone
FOXO4-DRI for sale, or FOXO4-DRI peptide for sale, means this page: one record, 2 sizes, a lot certificate for each. You can buy FOXO4-DRI online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Run these on us too. A supplier who cannot pass them is asking you to take their word for it, and their word is the one thing a certificate exists to replace.
- Check the certificate on the lab’s own site, not ours.
- See whether it was written for the seller.
- Match the lot number on the paper to the one on the vial.
- Look for a method and a date next to every number.
- Make sure identity was tested, not assumed.
Each of those is worked through, with what a failed check actually looks like, on verifying a certificate.
The FOXO4-DRI certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run — how to read one covers what each field does and does not cover. For FOXO4-DRI that means a mass spectrum landing on 5,358 g/mol for C228H388N86O64, the figure published against PubChem CID 167312269.
The certificate below belongs to one lot, and its number matches the one printed on the vial you receive. A real report for a different batch is still the wrong report.
| Size | Lot | Identity method | Purity | Test date |
|---|---|---|---|---|
| 2mg | Pending verification | Pending verification | Pending verification | Pending verification |
| 10mg | Pending verification | Pending verification | Pending verification | Pending verification |
No lot documentation is published for FOXO4-DRI yet. Rather than display a placeholder certificate, this record shows the gap until each field has been verified against the lot in hand. The certificate index lists every lot the moment its report clears.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to FOXO4-DRI.
Where the FDA stands on FOXO4-DRI
The FDA has not approved this compound for anything, and nothing in this catalogue is a medicine. Where a compound stands legally depends on what it is, what form it is in, what it is being used for and which country you are in, and it changes over time, so the status shown here carries the date it was last checked.
Status verified 2026-08-25. Regulatory positions move; check the primary source before relying on any summary, including this one.
It is sold here as laboratory material under the research-use restriction that closes this page, which is not an approval, and not a statement that the compound is safe, effective or right for any purpose.
FOXO4-DRI research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarise what it found. A supplier is not a neutral judge of evidence about its own catalogue.
FOXO4-DRI is a designed peptide with two distinct pieces of engineering behind it. The mechanism is a targeted disruption of a protein-protein interaction: senescent cells accumulate irreparable damage but avoid apoptosis, and FOXO4 was identified as a pivot in how they manage that, holding p53 in a configuration that keeps the cell alive. A peptide that perturbs the FOXO4-p53 interaction causes p53 nuclear exclusion and cell-intrinsic apoptosis selectively in senescent cells — the selectivity comes from the fact that non-senescent cells are not depending on that interaction for survival.
The second piece of engineering is the D-retro-inverso construction: the peptide is built from D-amino acids in reverse sequence order, which preserves the spatial arrangement of side chains that determines binding while making the backbone unrecognisable to proteases. That is a real and elegant stability solution, and it also means the molecule is a mirror-image construct rather than a natural sequence, with the analytical implications that carries.
| Reported observation | Model | Source |
|---|---|---|
| FOXO4 was identified as a pivot in senescent cell viability. A FOXO4 peptide perturbing the FOXO4-p53 interaction caused selective p53 nuclear exclusion and cell-intrinsic apoptosis in senescent cells. Under conditions where it was well tolerated in vivo, the peptide neutralised doxorubicin-induced chemotoxicity, and restored fitness, fur density and renal function in both fast-ageing Xpd mice and naturally aged mice. | human and mouse cell lines, fast-ageing Xpd mutant mice and naturally aged mice | Baar and colleagues, Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging, Cell (2017)Erasmus MC with the Buck Institute. Note the authors' own qualifier: "under conditions where it was well tolerated" — the tolerated window is doing real work in that sentence. |
Open questions. This is a high-profile single paper in a major journal, and the qualifier the authors themselves attach deserves more attention than it usually gets: the in vivo benefits were observed under conditions where the peptide was well tolerated, which is an explicit acknowledgement that a tolerability boundary exists and that the useful window sits below it. The mechanism is deliberate induction of apoptosis, so the compound is cytotoxic by design and its selectivity depends entirely on senescent cells' particular dependence on the FOXO4-p53 interaction.
Senescent cells are not uniformly harmful either — they have roles in wound healing and tumour suppression — so clearing them is not straightforwardly beneficial. There are no human data, no approved product, and the D-retro-inverso construction means an ordinary peptide identity assay must confirm stereochemistry, not just mass and sequence, which is a harder analytical question than it appears.
Each row above describes an observation in the stated model. None of it describes what FOXO4-DRI would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
Questions about FOXO4-DRI
Where to buy FOXO4-DRI Peptide, and can I get it online?
How much does FOXO4-DRI Peptide cost?
What is the cheapest way to buy FOXO4-DRI Peptide?
What is FOXO4-DRI used for?
How does FOXO4-DRI work, and what does it do?
How do I verify the certificate of analysis is real?
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
